1. ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP. (12th June 2019) Authors: Nowakowski, G.S.; Hong, F.; Scott, D.W.; Macon, R.; King, R.L.; Habermann, T.M.; Wagner‐Johnston, N.; Casulo, C.; Wade, J.L.; Nagargoje, G.G.; Reynolds, C.M.; Cohen, J.B.; Khan, N.; Amengual, J.; Richards, K.L.; Little, R.F.; Leonard, J.P.; Friedberg, J.W.; Kostakoglu, L.; Kahl, B.S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BCL2 mRNA or protein abundance is superior to gene rearrangement status in predicting clinical outcomes in patients with diffuse large B‐cell lymphoma. (June 2017) Authors: Li, Y.; Tyryshkin, K.; Good, D.; Farmer, P.; Scott, D.W.; Crocker, S.; Baetz, T.; LeBrun, D. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 288 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP. (June 2017) Authors: Kuruvilla, J.; Crump, M.; Villa, D.; Aslam, M.; Prica, A.; Scott, D.W.; Abdel‐Samad, N.; Couban, S.; Doucet, S.; Dudebout, J.; Fleury, I.; Fraser, G.; Larouche, J.; Shafey, M.; Skrabek, P.; Skamene, T.; Winch, C.; Shepherd, L.; Chen, B.E.; Hay, A.E. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CRYPTIC MYC AND BCL2 REARRANGEMENTS ARE AMONG A RANGE OF GENETIC MECHANISMS UNDERLYING THE DOUBLE HIT SIGNATURE IN NON‐DOUBLE HIT DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Hilton, L.K.; Alcaide, M.; Ben‐Neriah, S.; Jiang, A.; Grande, B.M.; Rushton, C.K.; Boyle, M.; Meissner, B.; Scott, D.W.; Morin, R.D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FUNCTIONAL CHARACTERIZATION OF NFKBIZ 3′ UTR MUTATIONS IN DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Arthur, S.E.; Mottok, A.; Cojocaru, R.; Jiang, A.; Grande, B.M.; Alcaide, M.; Rushton, C.; Ennishi, D.; Kumar Lat, P.; Davidson, J.; Bushell, K.R.; Audas, T.; Unrau, P.; Sen, D.; Gascoyne, R.D.; Marra, M.A.; Connors, J.M.; Morin, G.B.; Scott, D.W.; Steidl, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS—A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL. (June 2017) Authors: Scott, D.W.; Pitcher, B.; Liu, Y.; Boyle, M.; Mottok, A.; Said, J.; Chadburn, A.; Lai, R.; Jung, S.; Bartlett, N.L.; Leonard, J.P.; Kaplan, L.D.; Hsi, E.D. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. IDENTIFYING MUTATIONS ENRICHED IN RELAPSED‐REFRACTORY DLBCL TO DERIVE GENETIC FACTORS UNDERLYING TREATMENT RESISTANCE. (12th June 2019) Authors: Rushton, C.; Alcaide, M.; Cheung, M.; Thomas, N.; Arthur, S.; Michaud, N.; Daigle, S.; Davidson, J.; Bushell, K.; Yu, S.; Jain, M.; Shepherd, L.; Crump, M.; Mann, K.; Kuruvilla, J.; Assouline, S.; Johnson, N.; Scott, D.W.; Morin, R.D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. INTEGRATIVE GENOMIC ANALYSIS IDENTIFIES KEY PATHOGENIC CONCEPTS IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Mottok, A.; Hung, S.S.; Chavez, E.A.; Woolcock, B.; Telenius, A.; Chong, L.C.; Meissner, B.; Nakamura, H.; Gascoyne, R.D.; Connors, J.M.; Ben Neriah, S.; Mungall, A.J.; Marra, M.A.; Siebert, R.; Scott, D.W.; Savage, K.J.; Steidl, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OUTCOME OF PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET‐GUIDED APPROACH. (12th June 2019) Authors: Hayden, A.; Tonseth, P.; Villa, D.; Gerrie, A.S.; Scott, D.W.; Freeman, C.L.; Slack, G.W.; Parsons, C.; Pickles, T.; Wilson, D.; Connors, J.M.; Sehn, L.H.; Savage, K.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma. (12th June 2019) Authors: Vitolo, U.; Witzig, T.E.; Gascoyne, R.D.; Scott, D.W.; Zhang, Q.; Jurczak, W.; Özcan, M.; Hong, X.; Zhu, J.; Jin, J.; Belada, D.; Bergua, J.M.; Piazza, F.; Mócikova, H.; Molinari, A.L.; Yoon, D.H.; Cavallo, F.; Tani, M.; Izutsu, K.; Kato, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗